Form 4: Dianthus Therapeutics Director Receives Stock Option Grant

Director Alison Frances Lawton was granted 6,090 stock options in Dianthus Therapeutics, Inc. as part of an equity incentive.

Summary

• Director Alison Frances Lawton received a grant of 6,090 stock options on May 21, 2026.
• The options have an exercise price of $89.63 per share.
• The options are set to expire on May 21, 2036.
• Vesting occurs on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting of Stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• Results in potential future dilution of existing shareholders upon exercise of the options.

Risks

• The value of the options is dependent on the future market performance of the company's common stock.

Future Outlook

The options vest in full on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting of Stockholders, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board alignment with long-term strategic objectives.

Comparison to Industry Standards

• The use of time-based vesting tied to annual meetings is consistent with standard equity compensation practices for board members in mid-cap biotech firms.

Stakeholder Impact

• Minor potential dilution for existing shareholders upon future exercise of options.

Next Steps

• Vesting of options on the earlier of May 21, 2027, or the 2027 Annual Meeting of Stockholders.

Key Dates

Keywords

Dianthus Therapeutics, DNTH, Form 4, Insider Trading, Stock Options, Equity Compensation